JP2023509870A5 - - Google Patents

Info

Publication number
JP2023509870A5
JP2023509870A5 JP2022538909A JP2022538909A JP2023509870A5 JP 2023509870 A5 JP2023509870 A5 JP 2023509870A5 JP 2022538909 A JP2022538909 A JP 2022538909A JP 2022538909 A JP2022538909 A JP 2022538909A JP 2023509870 A5 JP2023509870 A5 JP 2023509870A5
Authority
JP
Japan
Prior art keywords
tlr7 agonist
rnai
pharmaceutically acceptable
oligonucleotide
cmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509870A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/087697 external-priority patent/WO2021130266A1/en
Publication of JP2023509870A publication Critical patent/JP2023509870A/ja
Publication of JP2023509870A5 publication Critical patent/JP2023509870A5/ja
Priority to JP2025196810A priority Critical patent/JP2026069791A/ja
Pending legal-status Critical Current

Links

JP2022538909A 2019-12-24 2020-12-22 Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ Pending JP2023509870A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025196810A JP2026069791A (ja) 2019-12-24 2025-11-17 Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/127972 2019-12-24
CN2019127972 2019-12-24
CN2020107002 2020-08-05
CNPCT/CN2020/107002 2020-08-05
PCT/EP2020/087697 WO2021130266A1 (en) 2019-12-24 2020-12-22 Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025196810A Division JP2026069791A (ja) 2019-12-24 2025-11-17 Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ

Publications (2)

Publication Number Publication Date
JP2023509870A JP2023509870A (ja) 2023-03-10
JP2023509870A5 true JP2023509870A5 (cg-RX-API-DMAC7.html) 2023-12-28

Family

ID=74194695

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538909A Pending JP2023509870A (ja) 2019-12-24 2020-12-22 Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ
JP2025196810A Pending JP2026069791A (ja) 2019-12-24 2025-11-17 Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025196810A Pending JP2026069791A (ja) 2019-12-24 2025-11-17 Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ

Country Status (9)

Country Link
US (1) US20230119360A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081639A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023509870A (cg-RX-API-DMAC7.html)
CN (1) CN114846140A (cg-RX-API-DMAC7.html)
AU (1) AU2020410993A1 (cg-RX-API-DMAC7.html)
CA (1) CA3163490A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007908A (cg-RX-API-DMAC7.html)
TW (1) TWI881004B (cg-RX-API-DMAC7.html)
WO (1) WO2021130266A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
AU2022384619A1 (en) * 2021-11-11 2024-04-11 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
KR20240131441A (ko) 2022-01-10 2024-08-30 오스퍼바이오 테라퓨틱스 인크. B형 간염 바이러스(hbv) 발현의 조절
EP4654973A1 (en) * 2023-01-26 2025-12-03 Aligos Therapeutics, Inc. Hepatitis b combination therapies
WO2024221135A1 (en) * 2023-04-23 2024-10-31 Ausper Biopharma Co., Ltd. Oligonucleotides for use in modulating immune responses against hepatitis b viral infection
CN119913146A (zh) * 2023-09-28 2025-05-02 北京凯因科技股份有限公司 用于抑制乙型肝炎病毒的siRNA及其用途
WO2025199466A1 (en) 2024-03-22 2025-09-25 Purdue Research Foundation Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use
TW202608468A (zh) * 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
WO2026131801A1 (en) * 2024-12-17 2026-06-25 F. Hoffmann-La Roche Ag Double stranded oligonucleotide for modulating jak1 expression

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Rna 간섭의 rna 서열 특이적인 매개체
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
WO2003040395A2 (en) 2001-11-07 2003-05-15 Applera Corporation Universal nucleotides for nucleic acid analysis
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
ES2459368T3 (es) 2004-12-17 2014-05-09 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
WO2007085485A2 (en) 2006-01-27 2007-08-02 Santaris Pharma A/S Lna modified phosphorothiolated oligonucleotides
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
EP2410053B2 (en) 2006-10-18 2020-07-15 Ionis Pharmaceuticals, Inc. Antisense compounds
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2010033225A2 (en) 2008-09-22 2010-03-25 Dicerna Pharmaceuticals, Inc. Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications
WO2010039543A2 (en) 2008-09-23 2010-04-08 Traversa Therapeutics, Inc. Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US20140303235A1 (en) 2011-08-11 2014-10-09 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
CN104837501B (zh) * 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
EP2928877B1 (en) 2012-12-06 2020-01-22 Merck Sharp & Dohme Corp. Disulfide masked prodrug compositions and methods
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
MX367083B (es) 2013-06-27 2019-08-05 Roche Innovation Ct Copenhagen As Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
PL3114128T3 (pl) * 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
AU2015329974B2 (en) 2014-10-10 2019-06-20 F. Hoffmann-La Roche Ag GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
EP3204392A1 (en) 2014-10-11 2017-08-16 F. Hoffmann-La Roche AG Compounds for use in the treatment of infectious diseases
TWI769565B (zh) 2014-11-10 2022-07-01 美商阿尼拉製藥公司 B型肝炎病毒(HBV)iRNA組成物及其用途方法
HUE053704T2 (hu) 2014-12-08 2021-07-28 Hoffmann La Roche 3-szubsztitutált 5-amino-6H-tiazolo[4,5-d]pirimidin-2,7-dion vegyületek vírusfertõzések kezelésére és megelõzésére
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
CN107427514B (zh) * 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
CN107592864B (zh) * 2015-05-12 2021-04-16 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
WO2017178656A1 (en) 2016-04-14 2017-10-19 Roche Innovation Center Copenhagen A/S TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
WO2017211791A1 (en) * 2016-06-07 2017-12-14 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and a tlr7 agonist
WO2018098328A1 (en) 2016-11-23 2018-05-31 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
IL307295A (en) * 2017-01-06 2023-11-01 Hoffmann La Roche Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[5,4-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran -2-yl]propyl]acetate
EP3684377B1 (en) * 2017-10-20 2022-12-07 Dicerna Pharmaceuticals, Inc. Methods for treating hepatitis b infection

Similar Documents

Publication Publication Date Title
JP7195360B2 (ja) Tlr7作動薬およびhbvカプシド集合阻害剤を用いた併用処置
KR101687841B1 (ko) 톨-유사 수용체의 조절제
US20120251497A1 (en) Inhibitors of hepatitis c virus
JP7034162B2 (ja) インフルエンザウイルス複製の阻害剤及びその使用
JP2018520685A (ja) B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
JP2022515778A5 (cg-RX-API-DMAC7.html)
HK1255463A1 (zh) Hbv衣壳组装抑制剂和干扰素的组合疗法
JP2012519691A5 (cg-RX-API-DMAC7.html)
US9694028B2 (en) 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
JP2006503850A5 (cg-RX-API-DMAC7.html)
JP2024544532A5 (cg-RX-API-DMAC7.html)
RU2002127413A (ru) ПРИМЕНЕНИЕ ПИРИДО[3,2-е]-ПИРАЗИНОНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
WO2019177937A1 (en) Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
JP2025509830A5 (cg-RX-API-DMAC7.html)
CN101175495A (zh) 联合疗法
JP2024527380A5 (cg-RX-API-DMAC7.html)
JP7749545B2 (ja) Tlr7作用薬を含む薬物の組み合わせ
CN120529909A (zh) 乙型肝炎组合疗法
CN116509862A (zh) 乐伐替尼和vic-1911在制备抑制癌症的药物中的应用
TW202321255A (zh) 經取代之三環醯胺及其類似物的合成
EA048951B1 (ru) Оксаламидозамещенные трициклические ингибиторы вируса гепатита в
HK1245082B (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
NZ733805B2 (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor